Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Miller

Showing results (191-200 of 215) with videos related to

Pageof 22
Sort By:
Annals of Clinical and Translational Neurology|October 7, 2014
Molecular mechanism underlying the impact of vitamin D on disease activity of MSKassandra L Munger, Karl Köchert, Kelly C Simon, et al.
Multiple Sclerosis and Related Disorders|May 31, 2016
HLA-DRB*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosisÖzgür Yaldizli, Varun Sethi, Matteo Pardini, et al.
Multiple Sclerosis and Related Disorders|February 8, 2018
Response to the commentary of Yates RL and DeLuca GC on the study: HLA-DRB1*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosisÖzgür Yaldizli, Varun Sethi, Matteo Pardini, et al.
Nature Reviews. Neurology|December 7, 2011
MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trialsFrederik Barkhof, Jack H Simon, Franz Fazekas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 1, 2015
DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?Steven H P van de Pavert, Nils Muhlert, Varun Sethi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 8, 2016
Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosisMatteo Pardini, Carole H Sudre, Ferran Prados, et al.
Journal of Magnetic Resonance Imaging : JMRI|September 27, 2007
Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAXBas Jasperse, Paola Valsasina, Veronica Neacsu, et al.
Lancet (London, England)|October 31, 2008
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLudwig Kappos, Ralf Gold, David H Miller, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 17, 2010
Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre studyMarco Rovaris, Maria A Rocca, Frederik Barkhof, et al.
Neurology|February 15, 2015
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyDavid H Miller, Robert J Fox, J Theodore Phillips, et al.
Pageof 22

Showing results (191-200 of 215) with videos related to

Sort By:
Pageof 22
Annals of Clinical and Translational Neurology|October 7, 2014
Molecular mechanism underlying the impact of vitamin D on disease activity of MSKassandra L Munger, Karl Köchert, Kelly C Simon, et al.
Multiple Sclerosis and Related Disorders|May 31, 2016
HLA-DRB*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosisÖzgür Yaldizli, Varun Sethi, Matteo Pardini, et al.
Multiple Sclerosis and Related Disorders|February 8, 2018
Response to the commentary of Yates RL and DeLuca GC on the study: HLA-DRB1*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosisÖzgür Yaldizli, Varun Sethi, Matteo Pardini, et al.
Nature Reviews. Neurology|December 7, 2011
MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trialsFrederik Barkhof, Jack H Simon, Franz Fazekas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 1, 2015
DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?Steven H P van de Pavert, Nils Muhlert, Varun Sethi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 8, 2016
Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosisMatteo Pardini, Carole H Sudre, Ferran Prados, et al.
Journal of Magnetic Resonance Imaging : JMRI|September 27, 2007
Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAXBas Jasperse, Paola Valsasina, Veronica Neacsu, et al.
Lancet (London, England)|October 31, 2008
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLudwig Kappos, Ralf Gold, David H Miller, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 17, 2010
Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre studyMarco Rovaris, Maria A Rocca, Frederik Barkhof, et al.
Neurology|February 15, 2015
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyDavid H Miller, Robert J Fox, J Theodore Phillips, et al.
Pageof 22